Tananuvat Napaporn, Winaikosol Pawara, Niparugs Muanploy, Chaidaroon Winai, Tangmonkongvoragul Chulaluck, Ausayakhun Somsanguan
Chiang Mai University LASIK Center, Center for Medical Excellence, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Clin Ophthalmol. 2021 Dec 22;15:4775-4785. doi: 10.2147/OPTH.S346992. eCollection 2021.
To evaluate the 12-months outcomes of photorefractive keratectomy (PRK) in patients with high myopia (≥ 6.0 diopters, D) compared with low-to-moderate myopia (< 6.0 D).
Records of 46 patients (69 eyes) who underwent PRK for myopic and astigmatic correction between October 2015 and December 2018 were reviewed. High myopic eyes (29 eyes) were compared with low-to-moderate myopic eyes (40 eyes). All surgeries were adjunct with 0.02% mitomycin C intraoperatively. Measured outcomes included postoperative uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent, corneal haze rate, and any complications.
At 12 months post-PRK, 26 eyes (89.7%) in the high myopia and 39 eyes (97.5%) in the low-to-moderate myopia group had UDVA ≥ 20/20, (p=0.30). Average postoperative logMAR UDVA at 12 months was -0.04 (20/18) and -0.11 (20/15) for the high myopia and low-to-moderate myopia groups, respectively. No eyes in either group had residual refractive errors >1 D. No eyes in both groups developed significant corneal haze at month 12. No eyes had a loss of greater than two Snellen lines of CDVA at 12 months post-surgery. The efficacy and safety indices at 12 months post-surgery were not significantly different between groups (1.06±0.26 vs.1.14±0.27, p =0.25 and 1.14±0.27 vs 1.17±0.26, p=0.60 for low-to-moderate myopia vs high myopia groups, respectively).
PRK with high myopic correction provides excellent refractive outcomes and is safe, compared to those of low-to-moderate myopic correction.
评估与低度至中度近视(<6.0屈光度,D)患者相比,高度近视(≥6.0屈光度)患者接受准分子激光角膜切削术(PRK)的12个月疗效。
回顾性分析2015年10月至2018年12月期间接受PRK矫正近视和散光的46例患者(69只眼)的病历。将高度近视眼(29只眼)与低度至中度近视眼(40只眼)进行比较。所有手术术中均联合使用0.02%丝裂霉素C。测量的结果包括术后裸眼远视力(UDVA)、矫正远视力(CDVA)、显验光球镜等效度、角膜混浊率及任何并发症。
PRK术后12个月时,高度近视组26只眼(89.7%)和低度至中度近视组39只眼(97.5%)的UDVA≥20/20(p=0.30)。高度近视组和低度至中度近视组术后12个月时平均logMAR UDVA分别为-0.04(20/18)和-0.11(20/15)。两组均无残留屈光不正>1D的眼。两组在术后12个月时均无眼出现明显角膜混浊。术后12个月时,两组均无眼的CDVA下降超过两行Snellen视力表。术后12个月时,两组的疗效和安全性指标无显著差异(低度至中度近视组与高度近视组分别为1.06±0.26对1.14±0.27,p =0.25;1.14±0.27对1.17±0.26,p=0.60)。
与低度至中度近视矫正相比,高度近视矫正的PRK提供了优异的屈光效果且安全。